Tamiflu approved for pediatric use in EU
Swiss drug major Roche's flagship antiviral Tamiflu (oseltamivir) has received approval from European regulators for the prevention of influenza in children aged one to 12 years.
Tamiflu is already indicated for the treatment of the disease in adults and children aged one year and above and for the prevention of influenza in adults and adolescents. The application was based on results from a subset of pediatric patients in a clinical study where the drug was used for the management of influenza in households, which showed that Tamiflu patients together with post-exposure prophylaxis of other household members is more effective in preventing secondary spread of infection in the group of people than treating the patient alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze